Inflammatory bowel disease (IBD) is associated with lifetime morbidity and the onset of disease frequently occurs in early life. Although IBD manifests throughout all ethnic groups, there has been marked heterogeneity in its incidence, prevalence, manifestation, and outcome. We sought to study the incidence, prevalence, and survival of ulcerative colitis (UC) and to examine the evolution and prognostic predictors of Crohn's disease (CD) and UC among Hong Kong Chinese. A total of 4 studies were performed to address these issues. One longitudinal cohort study examined the incidence, prevalence, survival and phenotypic changes of UC. Two other longitudinal cohort studies evaluated the phenotypic evolution of CD. One of them specifically compared the course of disease between patients with and patients without upper gastrointestinal tract phenotype. The final retrospective study identified clinical factors that predicted the occurrence of corticosteroid dependency and refractoriness in patients with IBD. The annual age-standardized incidence rate and point prevalence of UC per 100,000 Hong Kong Chinese in 2006 were 2.1 (95% CI: 1.1-3.7) and 26.5 (95% CI: 22.6-30.9), respectively. Incidence of UC has increased 6 times over the past two decades. The overall survival of UC patients was similar to the expected survival of the Hong Kong population. Phenotypic changes in CD also occurred in Chinese patients in the same way as the white patients with respect to disease behavior, though at a slower rate. Similar to the white CD patients, the location of disease remained relatively stable over the course of disease. Chinese CD patients had more upper gastrointestinal tract phenotype which predicted the need of surgery and subsequent hospitalization. On the other hand, the rate of proximal extension of UC was less than 25% after 10 years. In CD, thrombocytosis predicted, whereas colonic disease negatively predicted corticosteroid dependency. Stricturing CD was associated with corticosteroid refractoriness. In UC, thrombocytosis and extensive colitis predicted corticosteroid dependency, whereas anemia predicted corticosteroid-refractory disease. The results of these studies are important in the planning of health service and they also assist in the formulation of treatment strategy. / Chow, Kai Lai. / "May 2009." / Advisers: Francis KL Chan; Joseph JY Sung. / Source: Dissertation Abstracts International, Volume: 72-01, Section: B, page: . / Thesis (M.D.)--Chinese University of Hong Kong, 2010. / Includes bibliographical references (leaves 193-235). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Electronic reproduction. Ann Arbor, MI : ProQuest Information and Learning Company, [200-] System requirements: Adobe Acrobat Reader. Available via World Wide Web.

A doença Inflamatória Intestinal (DII) é uma desordem caracterizada pela inflamação crônica do trato gastrointestinal. Os dois principais tipos de DII são a Retocolite Ulcerativa (RCU) e a Doença de Crohn (DC) e ambas cursam com importantes alterações no estado nutricional (EN). O objetivo deste estudo foi identificar as diferenças na composição corporal entre pacientes com DC, RCU e indivíduos saudáveis, além de comparar o estado nutricional dos três grupos de pacientes, ajustando para fatores que podem interferir no EN, como o uso atual de corticosteróides, a atividade física, a atividade de doença, a idade e o sexo. Foi realizado um estudo transversal que incluiu 101 pacientes com DII (50 com DC e 51 com RCU) e 35 indivíduos saudáveis, selecionados no Ambulatório do Hospital Universitário Pedro Ernesto (HUPE) da Universidade do Estado do Rio de Janeiro (UERJ). Foram colhidas informações sócio-demográficas e pessoais, tais como: prática de atividade física, tabagismo, doenças pregressas e procedimentos cirúrgicos prévios. Outras informações necessárias à pesquisa foram coletadas em prontuário médico. A avaliação antropométrica foi realizada por meio das seguintes medidas: peso corporal; altura; circunferências do braço, da cintura (CC) e do quadril; dobras cutâneas do tríceps, subescápula, supra-ilíaca e da coxa; e circunferência muscular do braço (CMB). A análise da composição corporal foi realizada por meio da bioimpedância elétrica (BIA), utilizando-se o aparelho Biodynamics modelo 450. As variáveis laboratoriais analisadas foram: glicose, hemograma completo, perfil lipídico, proteínas totais, albumina, globulina, velocidade de hemossedimentação e proteína C reativa. O peso, o índice de massa corporal, a CC e o percentual de gordura corporal calculado a partir da aferição das dobras cutâneas, foram menores nos pacientes com DC, quando comparados aos indivíduos saudáveis e/ou aos pacientes com RCU. A CMB foi menor nos pacientes com DC e RCU quando comparados aos indivíduos saudáveis, porém sem apresentar diferenças entre os dois grupos de pacientes. Por BIA, verificou-se que os pacientes com DC apresentaram valores de massa magra, massa celular corpórea, massa extracelular, água corporal total e água extracelular menores quando comparados aos indivíduos saudáveis. Os níveis séricos de colesterol total, proteínas totais e albumina, e a contagem total de hemácias foram menores nos indivíduos com DC quando comparados aos indivíduos do grupo controle e/ou aos indivíduos do grupo da RCU. Os pacientes com RCU exibem composição corporal semelhante à da população saudável. Em contraposição, os pacientes com DC apresentam EN amplamente comprometido com depleção de gordura corporal e massa magra em relação aos demais indivíduos / Inflammatory Bowel Disease (IBD) is a disorder characterized by diffuse inflammation of the gastrointestinal tract. The two main types of IBD are ulcerative colitis (UC) and Crohn's disease (CD), both coursing with important changes in nutritional status (NS). The objective of this study was to identify differences in body composition between patients with CD, UC, and healthy subjects and to compare the NS of these three groups of patients, adjusting for factors that can interfere in NS such as current use of corticosteroids, physical activity, disease activity, age and sex. It was conducted a cross-sectional study which included 101 patients with IBD (50 with CD and 51 with UC) and 35 healthy subjects, selected at the Ambulatory of Pedro Ernesto University Hospital (HUPE) of the Rio de Janeiro State University (UERJ). Socio-demographic and personal information such as physical activity, smoking, prior diseases and previous surgical procedures were collected. Other necessary information for the research were collected from medical records. The anthropometric evaluation was carried out through the following measures: body weight; height; mid-arm, waist and hip circumferences; skinfold thickness of the triceps, subscapular, suprailiac, and thigh; and mid-arm muscle circumference (MAMC). The body composition analysis was performed by bioelectrical impedance (BIA) using the equipment Biodynamics model 450. The laboratory variables analyzed, included: glucose, complete blood count, lipid profile, total protein, albumin, globulin, erythrocyte sedimentation rate, and C-reactive protein. Weight, body mass index, waist circumference, and percentage body fat calculated from skinfold measurements were lower in CD patients compared to healthy subjects and/or the patients with UC. The MAMC was lower in patients with CD and UC compared to healthy subjects, but without showing differences between the two groups of patients. Through BIA, it was found that CD patients had values of lean body mass, body cell mass, extracellular mass, total body water, and extracellular water smaller when compared to healthy subjects. Seric levels of total cholesterol, total protein, and albumin, as well as red blood cell count and relative count of lymphocytes were lower in the individuals with CD than the individuals of the control group and/or the patients with UC. Patients with UC exhibit body composition similar to that of the healthy population. In contrast, CD patients have widely NS committed with depletion of body fat and lean mass in relation to other individuals.

A doença Inflamatória Intestinal (DII) é uma desordem caracterizada pela inflamação crônica do trato gastrointestinal. Os dois principais tipos de DII são a Retocolite Ulcerativa (RCU) e a Doença de Crohn (DC) e ambas cursam com importantes alterações no estado nutricional (EN). O objetivo deste estudo foi identificar as diferenças na composição corporal entre pacientes com DC, RCU e indivíduos saudáveis, além de comparar o estado nutricional dos três grupos de pacientes, ajustando para fatores que podem interferir no EN, como o uso atual de corticosteróides, a atividade física, a atividade de doença, a idade e o sexo. Foi realizado um estudo transversal que incluiu 101 pacientes com DII (50 com DC e 51 com RCU) e 35 indivíduos saudáveis, selecionados no Ambulatório do Hospital Universitário Pedro Ernesto (HUPE) da Universidade do Estado do Rio de Janeiro (UERJ). Foram colhidas informações sócio-demográficas e pessoais, tais como: prática de atividade física, tabagismo, doenças pregressas e procedimentos cirúrgicos prévios. Outras informações necessárias à pesquisa foram coletadas em prontuário médico. A avaliação antropométrica foi realizada por meio das seguintes medidas: peso corporal; altura; circunferências do braço, da cintura (CC) e do quadril; dobras cutâneas do tríceps, subescápula, supra-ilíaca e da coxa; e circunferência muscular do braço (CMB). A análise da composição corporal foi realizada por meio da bioimpedância elétrica (BIA), utilizando-se o aparelho Biodynamics modelo 450. As variáveis laboratoriais analisadas foram: glicose, hemograma completo, perfil lipídico, proteínas totais, albumina, globulina, velocidade de hemossedimentação e proteína C reativa. O peso, o índice de massa corporal, a CC e o percentual de gordura corporal calculado a partir da aferição das dobras cutâneas, foram menores nos pacientes com DC, quando comparados aos indivíduos saudáveis e/ou aos pacientes com RCU. A CMB foi menor nos pacientes com DC e RCU quando comparados aos indivíduos saudáveis, porém sem apresentar diferenças entre os dois grupos de pacientes. Por BIA, verificou-se que os pacientes com DC apresentaram valores de massa magra, massa celular corpórea, massa extracelular, água corporal total e água extracelular menores quando comparados aos indivíduos saudáveis. Os níveis séricos de colesterol total, proteínas totais e albumina, e a contagem total de hemácias foram menores nos indivíduos com DC quando comparados aos indivíduos do grupo controle e/ou aos indivíduos do grupo da RCU. Os pacientes com RCU exibem composição corporal semelhante à da população saudável. Em contraposição, os pacientes com DC apresentam EN amplamente comprometido com depleção de gordura corporal e massa magra em relação aos demais indivíduos / Inflammatory Bowel Disease (IBD) is a disorder characterized by diffuse inflammation of the gastrointestinal tract. The two main types of IBD are ulcerative colitis (UC) and Crohn's disease (CD), both coursing with important changes in nutritional status (NS). The objective of this study was to identify differences in body composition between patients with CD, UC, and healthy subjects and to compare the NS of these three groups of patients, adjusting for factors that can interfere in NS such as current use of corticosteroids, physical activity, disease activity, age and sex. It was conducted a cross-sectional study which included 101 patients with IBD (50 with CD and 51 with UC) and 35 healthy subjects, selected at the Ambulatory of Pedro Ernesto University Hospital (HUPE) of the Rio de Janeiro State University (UERJ). Socio-demographic and personal information such as physical activity, smoking, prior diseases and previous surgical procedures were collected. Other necessary information for the research were collected from medical records. The anthropometric evaluation was carried out through the following measures: body weight; height; mid-arm, waist and hip circumferences; skinfold thickness of the triceps, subscapular, suprailiac, and thigh; and mid-arm muscle circumference (MAMC). The body composition analysis was performed by bioelectrical impedance (BIA) using the equipment Biodynamics model 450. The laboratory variables analyzed, included: glucose, complete blood count, lipid profile, total protein, albumin, globulin, erythrocyte sedimentation rate, and C-reactive protein. Weight, body mass index, waist circumference, and percentage body fat calculated from skinfold measurements were lower in CD patients compared to healthy subjects and/or the patients with UC. The MAMC was lower in patients with CD and UC compared to healthy subjects, but without showing differences between the two groups of patients. Through BIA, it was found that CD patients had values of lean body mass, body cell mass, extracellular mass, total body water, and extracellular water smaller when compared to healthy subjects. Seric levels of total cholesterol, total protein, and albumin, as well as red blood cell count and relative count of lymphocytes were lower in the individuals with CD than the individuals of the control group and/or the patients with UC. Patients with UC exhibit body composition similar to that of the healthy population. In contrast, CD patients have widely NS committed with depletion of body fat and lean mass in relation to other individuals.

Des études de liaison et d’association génétiques ont permis d’identifier certains des facteurs de risque génétiques aux maladies inflammatoires de l’intestin (MII) dans la région chromosomique 3p21. Dans cette région, le polymorphisme nucléotidique simple (SNP) codant non-synonyme du gène MST1, rs3197999, encodant pour la mutation R689C, a été associé et répliqué à la fois à la colite ulcéreuse (CU) et à la maladie de Crohn (MC). Un autre SNP, corrélé à des SNP codants non-synonymes du gène MST1R, a également été associé à la MC. Afin de déterminer si d’autres variantes des gènes MST1 et MST1R sont associés à la CU, nous avons testé pour association des SNP de ces gènes. Seul un proxy de R689C a montré un signal d’association significatif aux MII, ce qui suggère que R689C est la variante causale aux MII dans le gène MST1. En cherchant à déterminer si la région 3p21 contenait plusieurs signaux d’association mutuellement indépendants, trois SNP ont été identifiés comme possible facteurs de risque indépendants, et ont été génotypés dans des cas de CU et de MC et des témoins, puis nos résultats d’association ont été combinés à ceux provenant de trois autres cohortes indépendantes. Les trois SNP, R689C (MST1), rs6802890 et rs7629936 (CDHR4), sont associés aux MII, mais une étude d’association conditionnelle suggère qu’il existe en fait deux signaux d’association mutuellement indépendants dans la région 3p21. Le signal principal provient de R689C, une mutation de la protéine MSP. Cette protéine a un rôle dans l’inflammation chez les macrophages murins, et la migration, la cicatrisation et la survie chez les cellules épithéliales. Dans cette étude, le rôle de la MSP a été investigué dans des modèles de macrophages humains et de cellules épithéliales de côlon, et seule la phosphorylation d’AKT, un acteur dans la voie de signalisation de la survie cellulaire, a été modulée par la MSP dans nos modèles. Ce projet a donc permis d’apporter des connaissances sur les facteurs de risques génétiques aux MII dans la région 3p21, en identifiant 2 signaux d’association indépendants, et en nous informant sur le rôle de MST1, duquel provient le signal d’association principal, chez les cellules humaines. / Linkage studies and association studies allowed the discovery of some of the genetic risk factors of inflammatory bowel disease (IBD) in the chromosomal region 3p21. In this region, the non-synonymous coding single nucleotide polymorphism (SNP) rs3197999, situated in the gène MST1 and encoding for the mutation R689C, has been associated to UC and CD multiple times, and an other SNP, correlated to non-synonymous coding SNPs in the gene MST1R, has also been associated to CD. In order to verify if other variants of MST1 and MST1R are associatied to UC, we tested the association of some of their SNPs. Apart from R689C, only its proxy showed a significative association signal to IBD. It suggests that R689C might be the causal variant of IBD in the region 3p21. In the aim to determine if the region 3p21 has multiple independant association signals, 3 SNPs have been identified, from the results of a published meta-analysis of UC genome-wide association studies, as being possibly independant risk factors for UC based on their correlation. Their association to IBD and their independance have been tested by genotyping them in a cohort composed of controls, and UC and CD cases. The results of the association tests have been combined, in a meta-analysis, to the results of 3 other independent association studies. The 3 SNPs, R689C (MST1), rs6802890 and rs7629936 (CDHR4) are associated to IBD, but the results of the subsequent conditional association tests suggest that there is only 2 independant association signals in the region 3p21. The main signal is raising from R689C, a mutation of the protein MSP. According to published studies, this protein has a function in the inflammation in murine macrophages, and also in the scattering, wound healing and survival of epithelial cells. In this thesis, we investigated the role of MSP in human macrophage models and in human côlon epithelial cells, and it has been show that MSP modulates the phosphorylation of AKT, an actor in the pathway of cellular survival. This project brought some knowledges about the IBD genetic risk factors in the region 3p21. We identified 2 independent association signals to IBD in this region, and the main signal is coming from a SNP in MST1, a gene which has a role, based on our results, in the survival in human colon epithelial cells.

HNF4[alpha] est un facteur de transcription de la famille des récepteurs nucléaires hormonaux dont le rôle dans l'organogenèse et le maintien des fonctions hépatiques est de mieux en mieux décrit. Cependant, son rôle dans le développement et le maintien des fonctions gastrointestinales est peu connu. Il en va de même pour le facteur de transcription CUX1 au sein de de la muqueuse intestinale. Nous avons ainsi décidé d'utiliser l'invalidation conditionnelle d' HNF4[alpha] (HNF4[alpha] [exposant]fx/fx) dans l'épithélium intestinal grâce à l'expression de la Cre-recombinase sous le contrôle du promoteur de 12.4 kb de la Villine (12.4kb-Villin .Cre). Les épithélia de l'intestin grêle et du côlon ont été étudiés au niveau de leur morphologie, de leur prolifération, de leur différenciation et de leur fonction à différents temps du développement de la souris. Nous avons dans un premier temps constaté que la morphogenèse de ces tissus se déroule normalement. Nous avons cependant observé que l'épithélium de l'intestin grêle présentait une légère augmentation de la prolifération et une modification des populations différenciées au profit des cellules entéroendocrines et caliciformes. Nous avons également identifié une réduction de la conductance de l'épithélium colique du à une dérégulation des canaux, transporteurs et pores impliqués dans la régulation du transport ionique. Des cibles directes d'HNF4[alpha], tel que la claudine-15, ont vu leur expression diminuer chez les animaux mutants ainsi que dans les maladies inflammatoires intestinales durant lesquelles HNF4[alpha] est réduit en expression. Cette modification dans le rôle crucial de la réabsorption des fluides auquel l'épithélium colique participe a eu pour effet d'entrainer une colite spontanée ressemblant à la colite ulcéreuse chez l'humain. En effet, une augmentation de l'inflammation, une augmentation du recrutement de leucocytes, une augmentation de la prolifération et une apparition de dysplasie épithéliale ont été observées. Les épithélia du grêle et du côlon ont également présenté une augmentation du stress oxydatif et de l'apoptose qui s'est avérée être protectrice contre la perte d'hétérozygocité de l'allèle Apc dans le modèle murin de tumorigenèse Apc Min/+ . En effet, les animaux pour lesquels l'invalidation de l'expression d'HNF4[alpha] a été effectuée par la Villine-Cre (Apc[exposant Min/+] HNF4[alpha] [exposant [delta]1EC] ), ont montré une réduction de 70% du nombre de polypes dans l'intestin grêle et une réduction de 90% du nombre de polypes dans le côlon. L'analyse des gènes impliqués dans la réduction des espèces réactives de l'oxygène a permis d'identifier la GSTK1 comme une nouvelle cible directe d'HNF4[alpha] tant dans l'épithélium de l'intestin grêle que dans le cancer colorectal. En effet, l'expression d'HNF4[alpha] chez les patients atteints du cancer colorectal s'est avérée augmentée chez 31 patients sur les 40 analysés. Ces augmentations oscillent entre 50 et 100% chez 22% des patients et de 100% et plus chez 40% des patients analysés ( n = 40). Les animaux Cux1[delta]HD ont quant à eux été étudiés au niveau de leur susceptibilité à un stress inflammatoire. Nous avons démontré que l'expression de CUX1 est nécessaire à la protection de l'inflammation aigüe et chronique et que les patients atteints des maladies inflammatoires intestinales répondent en augmentant l'expression de ce facteur. Nous croyons que l'expression de CUX1 permet de tempérer la réponse inflammatoire et permet aussi la migration et la prolifération de l'épithélium colique en réponse aux blessures causées par l'inflammation soutenue. Collectivement, ces études démontrent l'importance du réseau de régulation transcriptionnelle dans les voies gastrointestinales pour le maintien de l'homéostasie proliférative, fonctionnelle et inflammatoire de l'épithélium. La modulation de ces facteurs durant les pathologies suggère la possibilité d'intervenir thérapeutiquement sur ces facteurs afin de contrôler leurs cibles et ainsi contrer l'apparition, la progression ou la chronicité de ces maladies.

<p>UVOD: Hronične inflamatorne bolesti se ispoljavaju kao Kronova bolest i ulcerozni kolitis. Njihova značajnost ogleda se u hronicitetu kao i u stepenu u kom ograničavaju rast i razvoj dece i omladine. Brojne su posledice ovih oboljenja: dugotrajno izostajanje sa nastave, ograničavanje životnih aktivnosti i pojava komplikacija koje neretko zahvataju i druge organske sisteme. Etiologija je i dalje nerazja&scaron;njenja navodeći kao značajan hronični inflamatorni proces u genetski uslovljenih pojedinaca a provociranih nekim infektivnim agensom. Početkom 21. veka genetska istraživanja su otkrila osnovu nasleđivanja hroničnih inflamatornih oboljenja povezanih sa NOD2 genom. Kako je u pitanju organskim sistem koji je ograničeno pristupačan kliničkom pregledu, osnovu dijagnostike čine radiolo&scaron;ke metode. Kako je potrebno sprečiti kontinuirano izlaganje &scaron;tetnom dejstvu rendgenskog zračenja istraživanja se usmeravaju ka UZ i magnetnoj rezonanca. Na&scaron;e istraživanje se baziralo na mogućnostima ovih dveju metoda u svakodnevnom radu za dijagnostiku i dalje praćenje hroničnih inflamatornih bolesti creva. CILJEVI: Utvrditi senzitivnost i specifičnost ultrazvučne dijagnostike i magnetne resonance kod upalnih oboljenja creva u dečjem i adolescentnom uzrastu. Definisati i uporediti prednosti i ograničenja ultrazvučne dijagnostike sa dijagnostikom magnetne rezonace kod upalnih obolenja creva u dečjem i adolescentnom uzrastu. MATERIJAL I METODE: U istraživanje je uključeno 62. dece i adolescenata u toku prvog ataka bolesti ili ponovljenim fazama bolesti ili tokom redovnog praćenja u remisiji. Obuhvaćeni uzrast je od 4. do 18. godina. Potom su razvrstani u grupe na osnovu vrste pregleda i prisustva zadebljanja crevnog zida na A i B (pregled UZ), gde je A grupa imala zabeleženo zadebljanje crevnog zida preko 3 mm, a kod dece u grupi B debljina crevnog zida je bila između 2,5-3 mm. Sa druge strane na osnovu pregleda magnetnom rezonancom podeljeni su u A1 i B1 grupe, takođe po kriterijumu zadebljanja crevnog zida većeg od 3 mm (A1), odnosno između 2,5-3 mm (B1). Istraživanje je sprovedeno na Institutu za zdravstvenu za&scaron;titutu dece i omladine Vojvodine i Institutu za radiologiju Kliničkog centra Vojvodine. Prvi pregled načinjen je UZ a potom je načinjen pregled magnetnom rezonanacom. Podaci su obrađivani retrospektivno i prospektivno. Kriterijumi za uključivanje u studiju pored uzrasta bili su radiolo&scaron;ki: zadebljanje crevnog zida &gt;3mm, postojanje naru&scaron;ene arhitektonike crevnog zida, zadebljanje pojedinih crevnih segmenata-dužina segmenta, znaci fibroze, odsustvo peristaltike, izražena hiperemija na kolor Doppleru, transmuralni znaci upale, uvećani mezenterijalni limfni nodusi kao i kontrolni pregledi kod dece sa ranije ustanovljenom dijagnozom. Načinjena je endoskopija sa biopsijom radi postavljanja definitivne dijagnoze, potom se pristupilo statističkoj obradi dobijenih podataka. Izračunate su prosečne i standardne devijacije i frekvencije kao i pripadajući procenti. Određivane su maksimalne i minimalne vrednosti, medijane i interkvartalni raspon. Dobijeni podaci prikazani su u grafikonima i tabelama. Za parametrijske varijable upotrebljavan je Man &ndash; Vitni U test. Za kategoričke vrednosti upotrebljeni su &chi;2 i Fi&scaron;erov test. Nadalje su određivane senzitivnost, specifičnost kao i pozitivne i negativne prediktivne vrednosti. Veze između dva parametra uspostavljene su pomoću Pirsonove korelacione analize i linearnim regresionim modelom. Upotrebljen je program za obradu podataka SPSS 21 Statistics,a kao statistički značajne vrednosti uzete su vrednosti p&lt;0,05. REZULTATI: Nakon statističke obrade nije zabeležena signifikantnost u pogledu zastupljenosti hroničnih inflamatornih bolesti među polovima. Statistička značajnost pronađena je u pogledu uzrasta dece u akutnoj fazi kao i remisiji bolesti. Statistička značajnost je dobijena za posmatranu debljinu crevnog zida, hiperemiju creva, prisustvo fibroze u digestivnom traktu. Primećeno je da UZ bolje razgraničava decu sa akutnim oboljenjem po pitanju zahvaćenosti segmenata. Ostala posmatrana obeležja nisu nakon statističke obrade imala statistički značaju razliku kada se procenjuju ultrazvučno ili magnetnom rezonancom. ZAKLJUČAK: Inicijalne hipoteze ovog istraživanja su nakon obrade podataka i potvrđene. Određivanjem senzitivnosti i specifičnosti UZ i MR dobijene su sledeće vrednosti: senzitivnost UZ je 88,4% naspram 92,3% koliko ima pregled magnetnom rezonancom. U pogledu specifičnosti UZ ima 88% a magnetna rezonanca 91,6%. Verifikovano je da magnetna rezonanca bolje razvrstava decu u akutnoj fazi bolesti kao i decu u remisiji. Rezultati pozitivnih i negativnih verovatnoća odnosa ne predviđaju neuspeh nijednim od ova dva pregleda.</p> / <p>INTRODUCTION: Chronic inflammatory diseases are manifested through two clinical entities: Crohn&#39;s disease and ulcerative colitis. Their significance lies in the chronicity and the degree to which they restrict the growth and development of children and youth. There are many consenquences that come with the very nature of the disease, in addition to long-term absence from school, limiting life activities and the occurrence of complications that often affect other organ systems. The etiology of the disease has long been in favor of the theory that a chronic inflammatory process in genetically conditioned individual is provoking an inflammation due to a certain infectious agent. However, a step closer was made regarding the etiology of the disease - when the genetic basis of inheritance studies have revealed chronic inflammatory bowel diseases were associated with NOD2 gene. It is particularly important to prevent continuous exposure to the harmful effects of X-rays. Therefore, numerous studies have been made towards the validation of complementarity, accuracy and diagnostic capabilities of ultrasound and magnetic resonance imaging as noninvasive techniques. Our research was based on the capabilities of these two methods in their daily work for diagnosis and follow-up of chronic inflammatory bowel disease. OBJECTIVES: The objectives were to determine the sensitivity and specificity of ultrasound and magnetic resonance imaging in inflammatory bowel disease in children and adolescents. Furthermore, the aim was to define and compare the advantages and limitations between ultrasound diagnosis and magnetic resonance in inflammatory bowel disease in children and adolescents. MATERIAL AND METHODS: The study included 62 children and adolescents during the first attack of disease or recurrent stages of the disease, or during regular monitoring in remission. Patients included children of both sexes, aged 4-18. Then they were sorted into groups based on the type of the examination and the presence of a thickening of the intestinal wall into groups A and B - in these groups children were examined by ultrasound, A group had observed thickening of the intestinal wall &gt; 3 mm whereas children in group B had had thickening of the intestinal wall between 2,5-3 mm. Based on the review of MRI children were divided into groups A1 and B1, also according to the criterion of bowel wall thickening greater than 3mm (A1) and between 2,5-3mm (B1). The research was conducted at the Institute for Health Protection of Children and Youth and the Institute of Radiology, Clinical Center of Vojvodina. The first review was made by ultrasound, followed by the review of magnetic resonance. Data were analyzed retrospectively and prospectively. Criteria for inclusion in the study were: thickening of the intestinal wall greater than 3 mm, the existence of disturbed intestinal wall architectural structure, no clear distinction of layers, abnormal thickening of certain intestinal segments, signs of fibrosis, the absence of peristalsis, expressed hyperemia on color Doppler, transmural inflammation, increased mesenterial lymph nodes as well as check-ups for children with previously established diagnosis. Endosccopy with biopsy has made for the definitive diagnosis and then we approached statistical analysis of the data obtained. The data are presented in graphs and tables. For parametric variables we used Man - Whitney U test. For categorical values &chi;2 and Fisher&#39;s test were used. Further the sensitivity, specificity and positive and negative predictive values were determined. Relationship between these two parameters were established using Pearson correlation analysis and linear regression model. For data processing we used the program SPSS Statistics 21, statistically significant values were taken p values &lt;0.05. RESULTS: After statistical analysis there was no for the number of chronic inflammatory diseases between the sexes. Statistical significance was found in terms of age of the children during the acute phase as well as remission. Statistical significance was obtained for the observed thickness of the intestinal wall, intestinal hyperemia, the presence of fibrosis in the digestive tract. It was noted that US better demarcates children with acute disease in terms of involvement of segments. Other features are not observed as significant after the statistical analysis. CONCLUSION: The initial hypothesis of this study, after data processing were confirmed. By determining the sensitivity and specificity of ultrasound MRI results we came to the following results: sensitivity of ultrasound was 88,4% versus 92,3%, for magnetic resonance. In terms of specifics UZ has a 88% and 91,6% of magnetic resonance imaging. The classification of children in the acute phase of the disease as well as children in remission was better when MRI was used. The results of positive and negative predictions do not predict the probability of failure in neither of these methods.</p>

Des études d'associations pangénomiques ont démontré une relation entre le taux plasmatique de la vitamine B12 et le polymorphisme du gène FUT2 (fucosyltransferase 2). Dans des modèles expérimentaux, le statut sécréteur pour FUT2 a été impliqué dans la susceptibilité à l'infection par Helicobacter pylori (H. pylori). Nous avons évalué l'influence du polymorphisme FUT2 461 G>A sur les marqueurs du métabolisme des monocarbones dans deux populations ambulatoires en Europe et en Afrique de l'Ouest ainsi que la possible association entre l'infection par H. pylori et le polymorphisme de FUT2. Nous avons mis en évidence une influence de FUT2 461 G>A sur le taux plasmatique de la vitamine B12 mais n'avons pas retrouvé d'influence du statut sérologique pour H. pylori sur cette association, du moins chez les sujets ambulatoires en Europe et en Afrique de l'Ouest. L'hyperhomocystéinémie est un marqueur de carence en donneurs de méthyle. Plusieurs travaux ont évalué le taux plasmatique de l'homocystéine au cours des maladies inflammatoires chroniques de l'intestin (MICI) et ont abouti à des résultats mitigés. Par ailleurs, l'ampleur de l'association entre le métabolisme de l'homocystéine et les MICI reste méconnue. Nous avons réalisé une méta-analyse afin : (i) d'évaluer l'association entre le métabolisme de l'homocystéine et les MICI et (ii) d'étudier le risque de thrombose lié à l'hyperhomocystéinémie au cours des MICI. Le risque d'hyperhomocystéinémie était significativement plus élevé chez les patients avec une MICI en comparaison aux sujets contrôles. L'évaluation du risque de thrombose associé à l'hyperhomocystéinémie au cours des MICI requiert des études complémentaires. Un statut carencé en folates était associé à un impact plus fort du polymorphisme MTHFR C677T sur le risque primaire de MICI. L'hyperhomocystéinémie et plusieurs polymorphismes sur les gènes du métabolisme des monocarbones sont associés au risque primaire et à la sévérité de la maladie de Crohn (MC). L'hyperhomocystéinémie augmente l'activité de la superoxyde dismutase (SOD), un marqueur fiable et validé du stress oxydatif. A l'aide d'un SNP array Illumina exhaustif du métabolisme des monocarbones, nous avons (i) étudié les déterminants génétiques (single nucleotide polymorphisms, SNPs) associés au taux plasmatique de l'homocystéine et de la SOD chez des patients suivis pour une MC et (ii) recherché les SNPs associés à l'âge du diagnostic de la MC. Deux SNPs étaient indépendamment associés au taux plasmatique de l'homocystéine (MTHFR, AHCY). Cinq SNPs étaient indépendamment associés au taux plasmatique de la SOD. Parmi ces cinq SNPs, trois sont liés à la vitamine B12 (FUT2, CUBN, et TCN2), un aux folates (GGH), et un dernier à la synthèse cellulaire de l'homocystéine (AHCY). Par ailleurs, nous avons mis en évidence deux SNPs associés à un âge précoce du diagnostic de la MC (CHDH, ABCB1). / Genome wide association studies demonstrated an association between plasma vitamin B12 and FUT2 (fucosyltransferase 2). It has been suggested that the association between FUT2 and low plasma vitamin B12 level may be the consequence of an increased susceptibility to Helicobacter pylori (H. pylori) infection. We evaluated the association between FUT2 461G>A polymorphism and vitamin B12 and investigated whether the influence of FUT2 on H. pylori serology is part of the mechanisms that underlie this association, in two populations from Europe and West Africa. In this study we confirmed the influence of FUT2 461 G>A polymorphism on plasma vitamin B12 level and found no influence of H. pylori serological status on this association, at least in ambulatory subjects from Europe and West Africa. The magnitude of the association between homocysteine metabolism and inflammatory bowel diseases (IBD) is unknown while the association between hyperhomocysteinemia and thrombosis remains controversial in IBD. We conducted a systematic review of the literature and performed a meta-analysis to examine these issues. The risk of hyperhomocysteinemia is significantly higher in IBD patients when compared to controls. The risk assessment of hyperhomocysteinemia-related thrombosis in IBD requires further investigation. Deficient folate status is associated with a higher impact of MTHFR C677T polymorphism on IBD risk. Hyperhomocysteinemia and several gene variants of one-carbon metabolism are associated with the occurrence and severity of Crohn's disease (CD). Hyperhomocysteinemia results in part from methyl donors deficiency - which is frequent in patients with CD - and increases the activity of superoxide dismutase (SOD), a validated and reliable marker of oxidative stress. We designed a 384-plex GoldenGate oligo pool assay for the comprehensive one-carbon metabolism genotyping using Illumina platform. The aims of this study were (i) to assess genetic determinants of plasma homocysteine and superoxide dismutase (SOD) levels in patients with IBD and (ii) to look for single nucleotide polymorphisms (SNPs) associated with age at CD onset. Two SNPs were associated with plasma homocysteine level (MTHFR, AHCY). Five SNPs were independently associated with plasma SOD level. Of these five SNPs, three are related to vitamin B12 (FUT2, CUBN, and TCN2), one is related to folate (GGH), and the last one to homocysteine (AHCY). In addition, we identified two SNPs associated with early CD onset (CHDH, ABCB1)

Des études de liaison et d’association génétiques ont permis d’identifier certains des facteurs de risque génétiques aux maladies inflammatoires de l’intestin (MII) dans la région chromosomique 3p21. Dans cette région, le polymorphisme nucléotidique simple (SNP) codant non-synonyme du gène MST1, rs3197999, encodant pour la mutation R689C, a été associé et répliqué à la fois à la colite ulcéreuse (CU) et à la maladie de Crohn (MC). Un autre SNP, corrélé à des SNP codants non-synonymes du gène MST1R, a également été associé à la MC. Afin de déterminer si d’autres variantes des gènes MST1 et MST1R sont associés à la CU, nous avons testé pour association des SNP de ces gènes. Seul un proxy de R689C a montré un signal d’association significatif aux MII, ce qui suggère que R689C est la variante causale aux MII dans le gène MST1. En cherchant à déterminer si la région 3p21 contenait plusieurs signaux d’association mutuellement indépendants, trois SNP ont été identifiés comme possible facteurs de risque indépendants, et ont été génotypés dans des cas de CU et de MC et des témoins, puis nos résultats d’association ont été combinés à ceux provenant de trois autres cohortes indépendantes. Les trois SNP, R689C (MST1), rs6802890 et rs7629936 (CDHR4), sont associés aux MII, mais une étude d’association conditionnelle suggère qu’il existe en fait deux signaux d’association mutuellement indépendants dans la région 3p21. Le signal principal provient de R689C, une mutation de la protéine MSP. Cette protéine a un rôle dans l’inflammation chez les macrophages murins, et la migration, la cicatrisation et la survie chez les cellules épithéliales. Dans cette étude, le rôle de la MSP a été investigué dans des modèles de macrophages humains et de cellules épithéliales de côlon, et seule la phosphorylation d’AKT, un acteur dans la voie de signalisation de la survie cellulaire, a été modulée par la MSP dans nos modèles. Ce projet a donc permis d’apporter des connaissances sur les facteurs de risques génétiques aux MII dans la région 3p21, en identifiant 2 signaux d’association indépendants, et en nous informant sur le rôle de MST1, duquel provient le signal d’association principal, chez les cellules humaines. / Linkage studies and association studies allowed the discovery of some of the genetic risk factors of inflammatory bowel disease (IBD) in the chromosomal region 3p21. In this region, the non-synonymous coding single nucleotide polymorphism (SNP) rs3197999, situated in the gène MST1 and encoding for the mutation R689C, has been associated to UC and CD multiple times, and an other SNP, correlated to non-synonymous coding SNPs in the gene MST1R, has also been associated to CD. In order to verify if other variants of MST1 and MST1R are associatied to UC, we tested the association of some of their SNPs. Apart from R689C, only its proxy showed a significative association signal to IBD. It suggests that R689C might be the causal variant of IBD in the region 3p21. In the aim to determine if the region 3p21 has multiple independant association signals, 3 SNPs have been identified, from the results of a published meta-analysis of UC genome-wide association studies, as being possibly independant risk factors for UC based on their correlation. Their association to IBD and their independance have been tested by genotyping them in a cohort composed of controls, and UC and CD cases. The results of the association tests have been combined, in a meta-analysis, to the results of 3 other independent association studies. The 3 SNPs, R689C (MST1), rs6802890 and rs7629936 (CDHR4) are associated to IBD, but the results of the subsequent conditional association tests suggest that there is only 2 independant association signals in the region 3p21. The main signal is raising from R689C, a mutation of the protein MSP. According to published studies, this protein has a function in the inflammation in murine macrophages, and also in the scattering, wound healing and survival of epithelial cells. In this thesis, we investigated the role of MSP in human macrophage models and in human côlon epithelial cells, and it has been show that MSP modulates the phosphorylation of AKT, an actor in the pathway of cellular survival. This project brought some knowledges about the IBD genetic risk factors in the region 3p21. We identified 2 independent association signals to IBD in this region, and the main signal is coming from a SNP in MST1, a gene which has a role, based on our results, in the survival in human colon epithelial cells.

Advances in molecular immunology and rapid technical evolution during the past two decades have led to a new class of medicines called biologics. Recently, a large number of biologics, or biologic immunomodulators, directed towards an array of immune–mediated diseases, have entered the market. This has lead to a dramatic change in the immunotherapy of autoimmune diseases, as biologics present new potential to improve or substitute conventional immunosuppressive therapies. According to literature, biologics are used by only a small number of a health plan’s members, (approximately one per cent), but a single occurrence can be relatively expensive. Furthermore, there is an indication that the frequency of use and cost of biologics are on the rise, and as more biologics enter the market, health plans and employers face the challenge of controlling costs while ensuring that biologics are affordable. The general objective of this study was to determine the prevalence and cost of biologic immunomodulating medicine in the treatment of certain autoimmune diseases during the period 2005 to 2008 in a section of the private health care sector of South Africa, by employing a medicine claims database as a source to obtain necessary information. A quantitative, retrospective drug utilisation review (rDUR) was performed on computerised medication records (medicine claims data) for four consecutive years (i.e. 2005 to 2008) provided by a pharmacy benefit management company (PBM). The study population consisted of all patients on the database who received at least one medicine item with adalimumab, etanercept, infliximab, interferon beta–1a, interferon 1–b or rituximab as active ingredient and who were diagnosed with either rheumatoid arthritis (RA), multiple sclerosis (MS) or Crohn’s disease between 1 January 2005 and 31 December 2008. Between 2005 and 2008, an average of 1,305,201 patients appeared on the total database, and of these 0.055% (n = 713) received biologic immunomodulating medicine. More than two thirds of biological users were female and most patients who received these medicine items were between the ages of 39 and 64 years, followed by those patients aged between 25 and 39 years. Biologic immunomodulating medicine items (n = 11,914) and biologic prescriptions (n = 9,537) represented 0.016% of the total number of medicine items (N = 76,129,173) and 0.030% of the total number of prescriptions (N = 31,985,153). The percentage contribution of biologic immunomodulators to the total number of medicine items and prescriptions on the total database increased each year, and in four years’ time the percentage of all the medicine items on the total database that included biologic immunomodulators had tripled, from 0.009% to 0.023%. The total cost of biologic immunomodulating medicine accounted for 1.278% of the total cost (N = R7, 483,759,176.23) of all medication claimed through the PBM between 2005 and 2008. The percentage contribution of biologic immunomodulators to the total medicine expenditure also increased from one year to another for the four–year study period. The average cost of a biologic immunomodulating medicine item increased with 71.10% from 2005 (R5602.71 ± 2166.61) to (R9586.25 ± 5956.56) in 2008. The CPI for biologic immunomodulators, (CPI = 60.00 for 2005; CPI = 74.62.17 for 2006; CPI = 85.26 for 2007; and CPI = 86.96 for 2008) indicated that biologic immunomodulating medicine items were relatively expensive and the d–value between the average cost per biologic immunomodulator and the average cost per non–biological medicine item (d–value = 2.54 in 2005, d–value = 3.32 in 2006, d–value = 2.23 in 2007 and d–value = 1.59 in 2008) furthermore indicated that the impact of biological therapies was large and practically significant. Rheumatoid arthritis patients represented 19.78% of the total number of patients (n = 713) who claimed the biologic immunomodulators during the four–year period, MS patients (n = 172) represented 24.12% and Crohn’s patients (n = 11) represented 1.5%. Biological drugs prescribed to RA patients represented 0.28% (n = R20, 708,818.82) of the total cost (N = R7, 483,759,176.23) of all medication claimed through the PBM during the four–year period, while those prescribed to MS patients represented 0.41% (R30, 922,520.07) and those prescribed to Crohn’s disease patients represented 0.015% (R1, 108,568.02). Although biologic immunomodulating medicine items used in the treatment of RA, MS and Crohn’s disease are relatively expensive, it seems that the number of other medication prescribed to patients with these diseases decreased after treatment with biologics, which may influence the medicine treatment cost of these patients. It can be concluded that even though biologic immunomodulators are used by only a very small percentage of the total patient population in a section of the private health care sector of South Africa, they are relatively expensive and have a considerable impact not only the medical aid scheme, but also on the patient. / Thesis (M.Pharm (Pharmacy Practice))--North-West University, Potchefstroom Campus, 2011.

Advances in molecular immunology and rapid technical evolution during the past two decades have led to a new class of medicines called biologics. Recently, a large number of biologics, or biologic immunomodulators, directed towards an array of immune–mediated diseases, have entered the market. This has lead to a dramatic change in the immunotherapy of autoimmune diseases, as biologics present new potential to improve or substitute conventional immunosuppressive therapies. According to literature, biologics are used by only a small number of a health plan’s members, (approximately one per cent), but a single occurrence can be relatively expensive. Furthermore, there is an indication that the frequency of use and cost of biologics are on the rise, and as more biologics enter the market, health plans and employers face the challenge of controlling costs while ensuring that biologics are affordable. The general objective of this study was to determine the prevalence and cost of biologic immunomodulating medicine in the treatment of certain autoimmune diseases during the period 2005 to 2008 in a section of the private health care sector of South Africa, by employing a medicine claims database as a source to obtain necessary information. A quantitative, retrospective drug utilisation review (rDUR) was performed on computerised medication records (medicine claims data) for four consecutive years (i.e. 2005 to 2008) provided by a pharmacy benefit management company (PBM). The study population consisted of all patients on the database who received at least one medicine item with adalimumab, etanercept, infliximab, interferon beta–1a, interferon 1–b or rituximab as active ingredient and who were diagnosed with either rheumatoid arthritis (RA), multiple sclerosis (MS) or Crohn’s disease between 1 January 2005 and 31 December 2008. Between 2005 and 2008, an average of 1,305,201 patients appeared on the total database, and of these 0.055% (n = 713) received biologic immunomodulating medicine. More than two thirds of biological users were female and most patients who received these medicine items were between the ages of 39 and 64 years, followed by those patients aged between 25 and 39 years. Biologic immunomodulating medicine items (n = 11,914) and biologic prescriptions (n = 9,537) represented 0.016% of the total number of medicine items (N = 76,129,173) and 0.030% of the total number of prescriptions (N = 31,985,153). The percentage contribution of biologic immunomodulators to the total number of medicine items and prescriptions on the total database increased each year, and in four years’ time the percentage of all the medicine items on the total database that included biologic immunomodulators had tripled, from 0.009% to 0.023%. The total cost of biologic immunomodulating medicine accounted for 1.278% of the total cost (N = R7, 483,759,176.23) of all medication claimed through the PBM between 2005 and 2008. The percentage contribution of biologic immunomodulators to the total medicine expenditure also increased from one year to another for the four–year study period. The average cost of a biologic immunomodulating medicine item increased with 71.10% from 2005 (R5602.71 ± 2166.61) to (R9586.25 ± 5956.56) in 2008. The CPI for biologic immunomodulators, (CPI = 60.00 for 2005; CPI = 74.62.17 for 2006; CPI = 85.26 for 2007; and CPI = 86.96 for 2008) indicated that biologic immunomodulating medicine items were relatively expensive and the d–value between the average cost per biologic immunomodulator and the average cost per non–biological medicine item (d–value = 2.54 in 2005, d–value = 3.32 in 2006, d–value = 2.23 in 2007 and d–value = 1.59 in 2008) furthermore indicated that the impact of biological therapies was large and practically significant. Rheumatoid arthritis patients represented 19.78% of the total number of patients (n = 713) who claimed the biologic immunomodulators during the four–year period, MS patients (n = 172) represented 24.12% and Crohn’s patients (n = 11) represented 1.5%. Biological drugs prescribed to RA patients represented 0.28% (n = R20, 708,818.82) of the total cost (N = R7, 483,759,176.23) of all medication claimed through the PBM during the four–year period, while those prescribed to MS patients represented 0.41% (R30, 922,520.07) and those prescribed to Crohn’s disease patients represented 0.015% (R1, 108,568.02). Although biologic immunomodulating medicine items used in the treatment of RA, MS and Crohn’s disease are relatively expensive, it seems that the number of other medication prescribed to patients with these diseases decreased after treatment with biologics, which may influence the medicine treatment cost of these patients. It can be concluded that even though biologic immunomodulators are used by only a very small percentage of the total patient population in a section of the private health care sector of South Africa, they are relatively expensive and have a considerable impact not only the medical aid scheme, but also on the patient. / Thesis (M.Pharm (Pharmacy Practice))--North-West University, Potchefstroom Campus, 2011.